Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05VZE
|
||||
| Former ID |
DCL000005
|
||||
| Drug Name |
Marimastat
|
||||
| Synonyms |
Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
British Biotech plc; Schering-Plough
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H29N3O5
|
||||
| InChI |
InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
|
||||
| InChIKey |
OCSMOTCMPXTDND-OUAUKWLOSA-N
|
||||
| CAS Number |
CAS 154039-60-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
522350, 535020, 583701, 7979862, 10238309, 14801947, 14924356, 17397883, 29300006, 46504173, 46505547, 49895569, 53787966, 53801232, 57339285, 79310144, 81065908, 84982157, 103185380, 103959089, 104407372, 134338721, 135075285, 135295976, 135741642, 136949642, 137006512, 141965955, 144103595, 160964128, 163126222, 163685882, 170482757, 178101905, 179149995, 198945327, 202820837, 204369779, 223704625, 226420558, 241376039, 251920423, 252156666, 252450850, 252479498
|
||||
| Target and Pathway | |||||
| Target(s) | Matrilysin | Target Info | Inhibitor | [528049], [536340], [537040], [538064] | |
| Interstitial collagenase | Target Info | Inhibitor | [528049], [536340], [537040], [538064] | ||
| 72 kDa type IV collagenase | Target Info | Inhibitor | [528049], [536340], [537040], [538064] | ||
| Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | ||||
| p75(NTR)-mediated signaling | |||||
| Syndecan-1-mediated signaling eventsendothelinpathway:Endothelins | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Glucocorticoid receptor regulatory network | |||||
| AP-1 transcription factor network | |||||
| Syndecan-1-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events | |||||
| Plasma membrane estrogen receptor signaling | |||||
| Osteopontin-mediated events | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Direct p53 effectors | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| Syndecan-2-mediated signaling events | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation | |||||
| Basigin interactions | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1442490:Collagen degradation | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | Wnt Signaling Pathway and Pluripotency | ||||
| Activation of Matrix Metalloproteinases | |||||
| AGE/RAGE pathway | |||||
| Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway | |||||
| Bladder Cancer | |||||
| Degradation of collagen | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell surface interactions at the vascular wall | |||||
| Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| Ref 468274 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220). | ||||
| Ref 527314 | Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004 Dec 1;22(23):4683-90. | ||||
| Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
| Ref 528049 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | ||||
| Ref 536340 | Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. Epub 2006 Dec 12. | ||||
| Ref 537040 | Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009 Feb;15(2):RA32-40. | ||||
| Ref 538064 | Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.